(0.87%) 5 126.25 points
(0.20%) 38 364 points
(1.17%) 17 772 points
(0.50%) $83.99
(-2.63%) $1.595
(0.41%) $2 352.00
(1.09%) $27.65
(1.41%) $933.50
(-0.02%) $0.932
(0.01%) $10.95
(-0.01%) $0.799
(0.01%) $92.18
Live Chart Being Loaded With Signals
Infant Bacterial Therapeutics AB (publ), a clinical stage pharmaceutical company, develops drugs to prevent or treat rare diseases affecting premature infants in Sweden...
Stats | |
---|---|
Today's Volume | 914.00 |
Average Volume | 6 633.00 |
Market Cap | 1.14B |
EPS | SEK0 ( 2024-02-07 ) |
Next earnings date | ( SEK0 ) 2024-05-06 |
Last Dividend | SEK0 ( N/A ) |
Next Dividend | SEK0 ( N/A ) |
P/E | -8.78 |
ATR14 | SEK1.146 (1.31%) |
Infant Bacterial Correlation
10 Most Positive Correlations |
---|
10 Most Negative Correlations |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Infant Bacterial Financials
Annual | 2023 |
Revenue: | SEK77 000.00 |
Gross Profit: | SEK77 000.00 (100.00 %) |
EPS: | SEK-9.95 |
Q4 | 2023 |
Revenue: | SEK0 |
Gross Profit: | SEK0 (0.00 %) |
EPS: | SEK-3.04 |
Q3 | 2023 |
Revenue: | SEK64 000.00 |
Gross Profit: | SEK64 000.00 (100.00 %) |
EPS: | SEK-2.31 |
Q2 | 2023 |
Revenue: | SEK0 |
Gross Profit: | SEK0 (0.00 %) |
EPS: | SEK-2.57 |
Financial Reports:
No articles found.
Infant Bacterial
Infant Bacterial Therapeutics AB (publ), a clinical stage pharmaceutical company, develops drugs to prevent or treat rare diseases affecting premature infants in Sweden. The company's lead drug candidate is IBP-9414, to prevent necrotizing enterocolitis, as well as to improve feeding tolerance affecting premature infants. It is also developing IBP-1016 for the treatment of gastroschisis, a rare and severe disease in infants. The company was founded in 2013 and is based in Stockholm, Sweden.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators